Form 10-Q Intra-Cellular Therapies For: Mar 31

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/22/2026

1. USO
2. META
3. NVDA
4. SPY
5. DCOY
6. MSFT
7. VKTX
8. PRGS
9. ONON
10. CMPX

Go back to Form 10-Q Intra-Cellular Therapies For: Mar 31

Intra-Cellular Therapies (ITCI) PT Lowered to $96 at RBC Capital

May 7, 2024 12:44 PM EDT

RBC Capital analyst Brian Abrahams lowered the price target on Intra-Cellular Therapies (NASDAQ: ITCI) to $96.00 (from $100.00) while maintaining a Outperform rating.

The analyst comments "This morning ITCI reported 1Q24 earnings and we had a chance to catch up with mgmt to... More

JPMorgan on Intra-Cellular Therapies (ITCI): 'We continue to like ITCI stock'

May 7, 2024 12:32 PM EDT

JPMorgan analyst Jessica Fye reiterated an Overweight rating and $75.00 price target on Intra-Cellular Therapies (NASDAQ: ITCI)

The analyst comments "We continue to like ITCI stock on the back of solid 1Q results and with shares having come off of their post-data highs. ITCI reported 1Q24 revenue of $145mm,... More

Jefferies Positive on Intra-Cellular Therapies (ITCI): 'We like the setup ahead of the second MDD readout in late-Q2'

May 7, 2024 8:00 AM EDT

Jefferies analyst Andrew Tsai reiterated a Buy rating and $105.00 price target on Intra-Cellular Therapies (NASDAQ: ITCI).

The analyst comments "ITCI previously preannounced a Q1 beat (Caplyta sales were $145M vs cons $141M), and mgmt just reiterated its 2024 guidance of $645-675M. Quarterly... More